ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $4 | $5 | $1 | $1 |
| - Cash | $1 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $4 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 36.4% | 66.7% | 21.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.1% | 98.9% | 98.7% | 99.6% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 27.4% | -2.2% | -76.1% | -131.4% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 27.1% | -5.1% | -81.3% | -143.3% |
| EPS Diluted | 0.1 | -0.016 | -0.16 | -0.23 |
| % Growth | 721.1% | 89.9% | 30.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |